Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Blair, Hannah A.

doi:10.1007/s40272-021-00476-w

Cited by 20 publications

(15 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, inflammatory bowel disease has been found at a higher prevalence in psoriasis patients and is considered a comorbidity. 5,22,23 One young male patient discontinued the drug due to IBD at week 16. The patient was never diagnosed with Overall, the safety and efficacy of our tapering dose regimen were consistent with those of the previously recommended dose.…”

Section: Discussionmentioning

confidence: 99%

Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single‐center, uncontrolled, prospective study in 36 weeks

Chen

Zheng

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Secukinumab is a recombinant, fully human monoclonal anti-IL-17A antibody approved to treat moderate-to-severe psoriasis and psoriatic arthritis. Its effectiveness and safety have been confirmed, but a gradual increase in the secukinumab dosing interval has not been investigated. To assess the feasibility, efficacy, and safety of gradually increasing the secukinumab dosing interval; the interval duration was determined by changes in the Psoriasis Area and Severity Index scores. Patients with moderate-to-severe plaque psoriasis received secukinumab 300 mg subcutaneously at baseline and weeks 0, 1, 2, and 3. At week 4, the improvement from baseline PASI guided the next injection time until week 36. In total, 83 patients were recruited. PASI 75 was achieved by 80%, 96%, and 95% of patients at weeks 4, 12, and 36, respectively. PASI 90 was achieved by 54%, 95%, and 84% of patients at weeks 4, 12, and 36, respectively. PASI 100 was achieved by 28%, 89%, and 68% of patients at weeks 4, 12, and 36, respectively. The average PASI score (1.05 ± 1.83) was significantly lower at week 36 than at baseline. Most patients reached PASI 75 at week 36 in our modified study. This study may provide information for future biotherapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single‐center, uncontrolled, prospective study in 36 weeks

Chen

Zheng

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Secukinumab, a recombinant, fully human IL-17A inhibitor, has been approved for the treatment of pediatric psoriasis patients aged ≥6 years in both the USA and Europe ( 2 ). The efficacy of secukinumab in the management of pediatric plaque psoriasis was evaluated in two phase III trials ( 2 ). In a study by Bodemer et al ( 13 ), secukinumab achieved higher PASI 75/90/100 responses at week 52 than etanercept.…”

Section: Discussionmentioning

confidence: 99%

“…More significantly, a 3-year-old psoriasis patient treated with secukinumab was included in the research. Actually, secukinumab was recommended for use in patients over 6 years old ( 2 ). So, before the injection, the clinician emphasized that there was no case of use in children under 6 years old and repeatedly informed of the potential risks as well as benefits.…”

Section: Methodsmentioning

confidence: 99%

Biologics for psoriasis patients under 18 years of age: Real-world evidence from the Chinese psoriasis real world evidence research group

Zheng

Yan

et al. 2022

Front. Med.

View full text Add to dashboard Cite

BackgroundTreatment for pediatric psoriasis is challenging because of the lack of real-world evidence, especially for biological therapies.ObjectivesThis study evaluated the efficacy and safety of biologics in children with psoriasis based on real-world evidence.MethodsPediatric psoriasis patients aged <18 years who were treated with biologics in our hospital (2020–2022) were prospectively analyzed. Patients treated with adalimumab, secukinumab, or ixekizumab were followed up for at least 16 weeks, and 22 of 38 patients completed the 52-week observation period. Dermatologist raters were blinded to ensure the reliability of the PASI, BSA, and PGA score assessments. PASI 75 or PGA 0/1 at week 12 represented an efficient indicator.ResultsThirty-eight patients (20 males and 18 females; median age, 12.6 ± 4.1 years) were enrolled, and none were lost to follow-up. All participants were diagnosed with psoriasis, including plaque psoriasis (n = 36), nail psoriasis (n = 1), and pustular psoriasis (n = 1). Within 12 weeks, all patients achieved scores above PASI 75 and PGA 0/1. The average time to reach PASI 75 was 4.3 ± 2.0, 3.2 ± 1.8, and 2.4 ± 0.4 weeks in patients using adalimumab, secukinumab, and ixekizumab, respectively, and, 27.2% (3/11), 86.4% (19/22), and 75.0% (3/4) of these patients achieved PASI 100 at week 12, respectively. Moreover, 18 of 20 patients with plaque psoriasis maintained ≥PASI 75 after 52 weeks. The most commonly reported adverse effect was upper respiratory tract infection, and no severe adverse effects were reported.ConclusionsOur real-world data demonstrated the safety and effectiveness of adalimumab, secukinumab, and ixekizumab in children with psoriasis.

show abstract

“…4 Targeting of interleukin 17A (IL-17A) has also come to play a key role in treating PsA, 4,5 as the levels of IL-17A are elevated not only in plaque psoriasis (PPs) but also in psoriatic lesional skin, which can lead to the release of chemokines and proinflammatory cytokines and mediators of tissue damage. 6 Secukinumab, the first IL-17A inhibitor, was approved by the US Food and Drug Administration (FDA) in January 2015 and has since been used to treat PPs, 7 PsA, 8 ankylosing spondylitis (AS), 9 nonradiographic axial spondyloarthritis (nr-axSpA) and enthesitisrelated arthritis. 10 Secukinumab has recently become one of the most popular drugs for immune diseases due to its strong curative effect.…”

Section: Introductionmentioning

confidence: 99%

Toxicity signals associated with secukinumab: A pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database

Zheng¹,

Guo²,

Chen³

et al. 2022

Brit J Clinical Pharma

View full text Add to dashboard Cite

Aims Secukinumab, the first interleukin 17A inhibitor, is widely used to treat immune diseases, including plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. Recently, many studies have reported adverse events associated with secukinumab, including gastrointestinal disorders, infections and infestations, and hypersensitive and nervous system disorders. Objective Here, we aimed to explore the clinical characteristics, outcomes and time to onset of the four main toxicities of secukinumab using post‐marketing data. Methods Our study utilized data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database from 2015 to 2021, using disproportionality analysis. Toxicities were defined based on the standardized Medical Dictionary for Regulatory Activities queries. Two disproportionality methods were used to detect potential signals: information component (IC) and reporting odds ratio (ROR). The signals were defined as ROR025 > 1 and IC025 > 0. Results A total of 73 945 398 records were included in this study, of which 300 665 records were related to secukinumab. Diarrhoea (N = 3538), nasopharyngitis (N = 3458), pruritus (N = 4277) and rash (N = 3270) were the most common adverse events. Inflammatory bowel disease (IC025/ROR025 = 3.25/9.69), genital candidiasis (IC025/ROR025 = 3.46/11.54), dermatitis psoriasiform (IC025/ROR025 = 1.94/4.04) and anosmia (IC025/ROR025 = 1.62/3.17) had the highest IC025 values of all toxicities. The time to onset of the four toxicities was mainly concentrated in the first month. Some patients simultaneously presented with two or more toxicities. Conclusion This pharmacovigilance study systematically explored the four main toxicities of secukinumab and provided new safety signals based on past safety information. Some high‐risk signals need to be given attention.

show abstract

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Cited by 20 publications

References 16 publications

Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single‐center, uncontrolled, prospective study in 36 weeks

Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single‐center, uncontrolled, prospective study in 36 weeks

Biologics for psoriasis patients under 18 years of age: Real-world evidence from the Chinese psoriasis real world evidence research group

Toxicity signals associated with secukinumab: A pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database

Contact Info

Product

Resources

About